Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | CA12 | O43570 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | CA7 | P43166 | 1/20 | 0.59 |
| ▸ | CA9 | Q16790 | 1/20 | 0.59 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.57 |
| ▸ | HPGD | P15428 | 5/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.57 |
| ▸ | TLR2 | O60603 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5458 | 1.00 | MAPT (0.59) | MAPTTDP1HTTCA12CA1 | |
| SCHEMBL23277173 | 0.98 | MAPT (0.58) | MAPTTDP1HTTCA12CA1 | |
| SCHEMBL8649813 | 0.98 | MAPT (0.58) | MAPTTDP1HTTCA12CA1 | |
| SCHEMBL30463054 | 0.86 | KDM4E (0.59) | MAPTHTTCA12CA1CA2 | |
| SCHEMBL480276 | 0.86 | KDM4E (0.59) | MAPTTDP1HTTCA12CA1 | |
| SCHEMBL22588880 | 0.84 | KDM4E (0.57) | MAPTTDP1HTTCA12CA1 | |
| SCHEMBL29502905 | 0.84 | LMNA (0.57) | MAPTHTTCA12CA1CA2 | |
| SCHEMBL2066210 | 0.84 | KDM4E (0.57) | MAPTTDP1HTTCA12CA1 | |
| SCHEMBL312140 | 0.84 | LMNA (0.57) | MAPTHTTCA12CA1CA2 | |
| SCHEMBL5187364 | 0.83 | ALDH1A1 (0.55) | MAPTTDP1HTTCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023097322-A2 | SKIN CARE COMPOSITION | THE PROCTER & GAMBLE COMPANY (US) | 2023-06-01 | — | — | WO | claimed |
| EP-4712938-A1 | SKIN CARE COMPOSITION COMPRISING HYDROXYCINNAMIC ACID AND NIACINAMIDE DERIVATIVE | The Procter & Gamble Company (US) | 2026-03-25 | — | — | EP | disclosed |
| CN-115697951-B | Method for producing para-eugenol and/or ortho-eugenol | 法国特种经营公司 | 2025-02-11 | — | — | CN | disclosed |
| WO-2024243289-A2 | GUT MICROBE DERIVED AROMATIC AMINO ACID METABOLITES FOR DETECTION AND TREATMENT OF DISEASE | THE CLEVELAND CLINIC FOUNDATION (US) | 2024-11-28 | — | — | WO | disclosed |
| WO-2024238440-A1 | SKIN CARE COMPOSITION COMPRISING HYDROXYCINNAMIC ACID AND NIACINAMIDE DERIVATIVE | THE PROCTER & GAMBLE COMPANY (US) | 2024-11-21 | — | — | WO | disclosed |
| EP-4440538-A1 | METHOD OF IMPROVING THE APPEARANCE OF SKIN | The Procter & Gamble Company (US) | 2024-10-09 | — | — | EP | disclosed |
| CN-118679196-A | Polymer stabilizer based on methoxy-hydroxy-benzoic acid, plastic composition, method for stabilizing a plastic composition and stabilizer composition | 弗劳恩霍夫应用研究促进协会 | 2024-09-20 | — | — | CN | disclosed |
| CN-118679196-A | Polymer stabilizer based on methoxy-hydroxy-benzoic acid, plastic composition, method for stabilizing a plastic composition and stabilizer composition | 弗劳恩霍夫应用研究促进协会 | 2024-09-20 | — | — | CN | disclosed |
| EP-4288084-A1 | SKINCARE COMPOSITIONS AND METHODS OF USE THEREOF | Modern Meadow, Inc. (US) | 2023-12-13 | — | — | EP | disclosed |
| US-11801262-B2 | Antibiotic compositions | THIOREDOXIN SYSTEMS AB (SE) | 2023-10-31 | — | — | US | disclosed |
| US-11419938-B2 | Phenylephrine-containing liquid formulations | GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS LLC (US) | 2022-08-23 | — | — | US | disclosed |
| WO-2022170114-A1 | SKINCARE COMPOSITIONS AND METHODS OF USE THEREOF | MODERN MEADOW, INC. (US) | 2022-08-11 | — | — | WO | disclosed |
| US-11406712-B2 | Phenylephrine-containing liquid formulations | GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS LLC (US) | 2022-08-09 | — | — | US | disclosed |
| US-20220168226-A1 | SUBLINGUAL DELIVERY FOR MITIGATION OF SIDE EFFECTS ASSOCIATED WITH METFORMIN | Vivera Pharmaceuticals Inc. (US) | 2022-06-02 | — | — | US | disclosed |
| WO-2022102651-A1 | LUBRICANT BASE OIL | 花王株式会社 | 2022-05-19 | — | — | WO | disclosed |
| US-20220117901-A1 | SUBLINGUAL DELIVERY FOR MITIGATION OF SIDE EFFECTS ASSOCIATED WITH BREXPIPRAZOLE | Vivera Pharmaceuticals Inc. (US) | 2022-04-21 | — | — | US | disclosed |
| US-20220117900-A1 | SUBLINGUAL DELIVERY FOR MITIGATION OF SIDE EFFECTS ASSOCIATED WITH VORTIOXETINE | Vivera Pharmaceuticals Inc. (US) | 2022-04-21 | — | — | US | disclosed |
| US-20220096387-A1 | SUBLINGUAL DELIVERY FOR MITIGATION OF SIDE EFFECTS ASSOCIATED WITH LURASIDONE | Vivera Pharmaceuticals Inc. (US) | 2022-03-31 | — | — | US | disclosed |
| US-20220062189-A1 | Sublingual Delivery for Mitigation of Side Effects Associated with Sildenafil Citrate | Vivera Pharmaceuticals Inc. (US) | 2022-03-03 | — | — | US | disclosed |
| US-20220023223-A1 | SUBLINGUAL DELIVERY FOR MITIGATION OF SIDE EFFECTS ASSOCIATED WITH BLONANSERIN | Vivera Pharmaceuticals Inc. (US) | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11801262-B2 | Antibiotic compositions | MRPL21, RPS5, MRPS35 | MAPT 2298/4885TDP1 3199/4885HTT 4343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.